Video

Adam Simmons Outlines Efficacy of ALKS 3831 Across Subgroups of Patients With Schizophrenia

Adam Simmons, director of clinical program management, Alkermes, interviewed at the American Psychiatric Association Annual Meeting, discussed the efficacy of the investigational drug ALKS 3831 (olanzapine/samidorphan) in various patient populations.

Adam Simmons, director of clinical program management, Alkermes, interviewed at the American Psychiatric Association Annual Meeting, discussed the efficacy of the investigational drug ALKS 3831 (olanzapine/samidorphan) in various patient populations.

Transcript

What can the data presented at APA tell us about the effectiveness of ALKS 3831 compared with olanzapine across subgroups of patients?

In the data that we’re presenting here at the APA conference, what it is that we’ve shown is that the antipsychotic efficacy of olanzapine when combined with samidorphan is very similar across 3 different patient populations. One in patients that were treated in an outpatient basis; one in patients that were treated in an outpatient basis combined with schizophrenia and alcohol use disorder, and the third study we had looked at people who were acutely psychotic having an acute exacerbation of schizophrenia and comparing 3831 to placebo with olanzapine as a comparator. In that third study where we were specifically looking at antipsychotic efficacy, we did look at subgroups. We’re planning on presenting that data and describing it more in a manuscript that’ll be published in the future.

Related Videos
Steven Daniel Daveluy, MD, FAAD
Shawn Kwatra, MD, FAAD
Elizabeth Jones, MD, FAAD.
Brittany Craiglow, MD, FAAD
Lawrence F Eichenfield, MD, FAAD.
Douglas Flora, MD, FACCC
Rebecca Vasquez, MD, FAAD
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Annie Antar, MD, PhD, Johns Hopkins Medicine
SECO 2025
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo